Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019, filed May 2, 2019—not a Crescent BioPharma, Inc. filing as stated in the request metadata. GlycoMimetics is a clinical-stage biotechnology company with no approved drugs or product sales.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $11.77 million | $9.02 million; up 30% |
| General and administrative expense | $3.36 million | $2.86 million; up 18% |
| Operating loss | $15.13 million | $11.88 million |
| Interest income | $1.05 million | $0.36 million |
| Net loss | $14.08 million | $11.51 million |
| Basic and diluted loss per share | $0.33 | $0.33 |
| Cash used in operating activities | $14.35 million | $10.21 million |
| Cash and cash equivalents at quarter-end | $195.56 million | $209.92 million at Dec. 31, 2018 |
R&D growth primarily reflected uproleselan Phase 3 trial start-up and enrollment, manufacturing costs, and increased personnel costs. Higher interest income reflected the larger cash balance after the March 2018 stock offering. Gross margin is not meaningful because the company had no product revenue. The filing reports no borrowings; liabilities were $11.65 million, including $4.08 million in operating lease liabilities. Current assets were $198.39 million versus current liabilities of $8.31 million. Accumulated deficit was $214.63 million.
Business, programs, and material developments
- Uproleselan: The company’s Phase 3 trial in relapsed/refractory acute myeloid leukemia (AML) began enrollment in late 2018; top-line results were expected by the end of 2020. Q1 spending on the program was $7.87 million, up from $6.02 million.
- Additional uproleselan trials: A company/NCI-supported trial in older adults with untreated AML opened in early 2019, with its first patient enrolled in April. A Phase 2 HOVON trial targets newly diagnosed AML patients unable to tolerate intensive chemotherapy and high-risk myelodysplastic syndrome.
- GMI-1359: After a Phase 1 healthy-volunteer trial, the company anticipated starting a Phase 1b trial in breast cancer patients with bone metastases in the second half of 2019.
- Rivipansel: Pfizer controls further development and commercialization under an exclusive worldwide license. Pfizer’s Phase 3 trial enrollment was nearing completion, with top-line data expected later in 2019. No Pfizer revenue or milestone was recorded in Q1.
- Financing: No shares were sold under the company’s at-the-market facility during Q1; $80 million remained available at March 31. Q1 financing cash flow consisted of $30,554 from option exercises, compared with $128.6 million of net public-offering proceeds in Q1 2018.
Outlook, risks, and unusual items
Management said existing cash and expected interest should fund operations through at least preliminary results from the uproleselan Phase 3 trial, expected by the end of 2020. The filing also states the funds were expected to cover at least 12 months from filing. These estimates depend on assumptions and trial timing; spending and operating losses are expected to continue, and additional financing may be needed. Management warned that capital may not be available on acceptable terms, and that development delays, trial outcomes, regulatory approval, manufacturing, commercialization, reimbursement, and intellectual-property protection create substantial uncertainty. Profitability is not assured.
Adoption of lease accounting on January 1, 2019 added a right-of-use asset and lease liabilities; management said adoption did not materially affect earnings or cash flows. The company reported effective disclosure controls, no material change in internal controls, no material legal proceedings, and no material change to the risk factors from its 2018 Form 10-K.
Important facts for investors to verify
- Confirm the filing identity: the source document names GlycoMimetics, Inc., while the request metadata names Crescent BioPharma, Inc.
- Track actual timing and results of the uproleselan and Pfizer-led rivipansel trials against management’s stated expectations.
- Assess cash burn, trial/manufacturing spending, and whether the projected runway through uproleselan results remains supportable.
- Review the probability and timing of potential Pfizer milestones and royalties; these are contingent and no Q1 payment was recorded.
- Reconcile common shares: the balance sheet reports 43,180,169 outstanding at March 31, while the filing cover reports 43,181,169 as of April 30, 2019.